Scott Gottlieb Buys 1,000 Shares of Pfizer Inc. (NYSE:PFE) Stock

Pfizer Inc. (NYSE:PFE) Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Pfizer Stock Down 0.8 %

Pfizer stock opened at $28.08 on Friday. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54. The stock has a fifty day simple moving average of $29.03 and a two-hundred day simple moving average of $28.57. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The firm has a market cap of $159.12 billion, a price-to-earnings ratio of 37.95, a PEG ratio of 0.90 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. Pfizer’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period last year, the company earned ($0.17) EPS. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.98%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is currently 227.03%.

Analyst Ratings Changes

Several equities research analysts have issued reports on PFE shares. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Wells Fargo & Company raised their target price on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Sanford C. Bernstein began coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Finally, Barclays boosted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $33.58.

Institutional Investors Weigh In On Pfizer

A number of large investors have recently added to or reduced their stakes in PFE. Costello Asset Management INC grew its holdings in shares of Pfizer by 461.9% in the third quarter. Costello Asset Management INC now owns 56,925 shares of the biopharmaceutical company’s stock worth $1,647,000 after acquiring an additional 46,795 shares during the period. Covestor Ltd boosted its position in Pfizer by 371.6% in the third quarter. Covestor Ltd now owns 10,079 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 7,942 shares during the last quarter. XML Financial LLC grew its stake in shares of Pfizer by 1.5% during the 3rd quarter. XML Financial LLC now owns 182,019 shares of the biopharmaceutical company’s stock valued at $5,268,000 after purchasing an additional 2,690 shares during the period. Atria Investments Inc increased its position in shares of Pfizer by 1.1% during the 3rd quarter. Atria Investments Inc now owns 300,430 shares of the biopharmaceutical company’s stock valued at $8,694,000 after purchasing an additional 3,243 shares during the last quarter. Finally, Kerusso Capital Management LLC lifted its stake in shares of Pfizer by 6.5% in the 3rd quarter. Kerusso Capital Management LLC now owns 111,081 shares of the biopharmaceutical company’s stock worth $3,215,000 after purchasing an additional 6,759 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.